This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Investors: Mark Your 2005 Calendars

Successful biotech investors stay on top of the calendar, because they need to be proactive about clinical data and Food and Drug Administration action dates. Regular readers have had an insatiable appetite for previous biotech catalyst calendars, so here's my latest for 2005. It's not comprehensive, and some of the dates are approximations, but this should give biotech investors a good road map for the upcoming year.

FDA Approvals/Filing Dates

American Pharmaceutical Partners (APPX): Abraxane, breast cancer, Jan. 8, 2005;

Cyberonics (CYBX): VNS Therapy System, depression, Jan. 31, 2005;

Discovery Labs (DSCO): Surfaxin, respiratory distress syndrome (pediatrics), Feb. 13, 2005;

Millennium Pharmaceuticals (MLNM): Velcade, second-line multiple myeloma, March 29, 2005;

Celgene (CELG - Get Report): Revlimid, FDA filing for myelodysplastic syndrome (5 q minus), first quarter 2005. Revlimid, multiple myeloma phase III, second half 2005;

Cephalon (CEPH): Nuvigil, narcolepsy, sleep apnea, shift work sleep disorder FDA filing, first quarter 2005;

Amylin Pharmaceuticals (AMLN): Symlin, diabetes, March 20, 2005. Exenatide, diabetes, April 30, 2005;

Adolor (ADLR): Entereg, post-operative ileus, April 25, 2005;

ImClone Systems (IMCL): Erbitux, FDA filing for head and neck cancer, second quarter 2005.

Clinical Data

Aphton (APHT): Insegia, gastrointestinal cancer phase III, first quarter 2005;

Genaera (GENR): Squalamine, age-related macular degeneration phase II, first quarter 2005. Squalamine, age-related macular degeneration, phase III, year-end 2005;

Corgentech (CGTK): E2F Decoy, coronary artery bypass graft failure phase III, early 2005;

Cell Therapeutics (CTIC): Xyotax, non-small-cell lung cancer phase III, first quarter 2005;

Axonyx (AXYX): Phenserine, Alzheimer's disease phase II, first quarter 2005;

Encysive Pharmaceuticals (ENCY): Thelin, pulmonary arterial hypertension phase III, February 2005;

Biogen Idec (BIIB - Get Report), Elan (ELN): Tysabri, two-year multiple sclerosis data, first half 2005. Tysabri, Crohn's disease phase III (induction), rheumatoid arthritis phase II, midyear 2005;

Antigenics (AGEN): Oncophage, renal cell cancer phase III; second quarter 2005;

CV Therapeutics (CVTX): Ranexa, angina phase III, second quarter 2005;

Transkaryotic Therapies (TKTX): I2S, Hunter Syndrome phase III, June 2005. Dynepo, oncology phase III, first half 2005;

Onyx Pharmaceuticals (ONXX): BAY 43-9006, renal cancer phase III interim analysis, first half 2005.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IMCL $0.14 23.09%
AMGN $158.30 -1.41%
BIIB $274.99 -2.17%
CELG $103.41 -4.28%
AAPL $93.74 -1.15%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs